Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access...

Illumina, Inc. (NASDAQ: ILMN) and Pacific Biosciences (NASDAQ:PACB) today announced they have signed an agreement for Illumina to acquire Pacific Bios

‘ phase III QUARTZ study of new investigational inhaled combination treatment...

Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma Source:...

Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three...

SUZHOU, China, Dec. 16, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801) and Incyte (NASDAQ:INCY) today announced that th

European Commission approves Roche’s MabThera (rituximab) for a rare autoimmune disease

Source: globenewswire.com The European Commission has given approval to Roche’s drug MabThera (rituximab). This drug helps treat adults with moderate to severe pemphigus vulgaris (PV),...

Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line...

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive op

Boston Scientific Exercises Option to Acquire Millipede, Inc.

MARLBOROUGH, Mass., Dec. 27, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire th

Dr Reddys Laboratories launches Tadalafil Tablets USP in US market |...

Read more about Dr Reddys Laboratories launches Tadalafil Tablets USP in US market on Business Standard. The Cialis brand and generic had U.S. sales of approximately $1.7 billion MAT for the most recent twelve months ending in January 2019 according to IMS Health.

Vertex Appoints Charles Wagner as Chief Financial Officer | Business Wire

Vertex today announced the appointment of Charles Wagner as Executive Vice President and Chief Financial Officer, effective April 10, 2019.

Spark Therapeutics’ One-time Gene Therapy LUXTURNA Gets EU Approval

Spark Therapeutics (ONCE), a commercial gene therapy company, announced Friday that the European Commission has granted marketing authorization for LUXTURNA (voretigene neparvovec).

Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S. | Business Wire

Sun Pharma launches ready-to-infuse INFUGEM - the first and only chemotherapy product in a premixed, ready-to-infuse formulation - in the US.